{"nctId":"NCT00669955","briefTitle":"Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy","startDateStruct":{"date":"2008-06"},"conditions":["Helicobacter Infections"],"count":440,"armGroups":[{"label":"OAC 7 days","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Omeprazole, amoxicillin, clarithromycin"]},{"label":"OBMT 10 days","type":"EXPERIMENTAL","interventionNames":["Drug: Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole"]}],"interventions":[{"name":"Omeprazole, amoxicillin, clarithromycin","otherNames":[]},{"name":"Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole","otherNames":["Pylera"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Positive H. Pylori status;\n* Presence of upper gastro-intestinal symptoms;\n* Mental and legal ability to sign informed consent.\n\nExclusion Criteria:\n\n* Previous surgery of the GI tract;\n* Clinically significant impairment of renal or hepatic function;\n* Severe unstable cardiovascular, pulmonary or endocrine disease;\n* Barrett's oesophagus or high-grade dysplasia;\n* Dysphagia or vomiting as major symptoms.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Helicobacter Pylori Eradication Confirmed by Urea Breath Test","description":"H. pylori Eradication defined as a negative C13-UBT (urea breath test) result at both Week 6 and Week 10 follow-up visits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"166","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Experiencing Treatment Emergent Adverse Events.","description":"A treatment-emergent adverse event is defined as an event not present prior to exposure to the study medication or any event already present that worsens in either intensity or frequency following exposure to study medication up to 30 days after study discontinuation.\n\nAll safety analysis based on the safety population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]}]},{"type":"SECONDARY","title":"H. Pylori Eradication and Presence or Past History of Peptic Ulcers","description":"Eradication rates in the subset of patients with peptic ulcer (current or past history) at baseline are reported based on the per protocol population. Eradication must be confirmed at week 6 and week 10 by a negative Urea Breath Test conducted within the allocated windows.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Clarithromycin Resistance","description":"Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to clarithromycin at baseline. Resistance to clarithromycin defined as Minimum Inhibitory Concentration (MIC) of 1 ug/ml and above","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Metronidazole Resistance","description":"Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to metronidazole at baseline. Resistance to metronidazole defined as Minimum Inhibitory Concentration (MIC) above 8 ug/ml","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Compliance to Study Medications","description":"Overall compliance: number of capsules dispensed - number of capsules returned/Number of prescribed capsules X 100. Percentages based on safety population","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.58","spread":"10.71"},{"groupId":"OG001","value":"97.47","spread":"14.91"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Bismuth Plasma Concentrations Above the Toxic Level","description":"Tolerability of OBMT with respect to plasma bismuth concentrations: number of patients with bismuth concentrations above the toxic level (50 ug per liter)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":216},"commonTop":["Dyspepsia","Diarrhea","Abdominal pain upper","Dysgeusia","Headache"]}}}